Costanza Alciati, a pharma analyst at GlobalData, told BioSpace in an email that GLP-1s will definitely dominate the market in the near future, but new entrants into the space are already looking for the next drug class that could revolutionize the space. Companies taking an alternative approach are forecast to capture only a very small portion of the obesity marketroughly 6.3%across the seven major markets (U.S., France, Germany, Italy, Spain, UK and Japan) by the end of 2031, according to Sara Reci, a senior analyst at GlobalData
And then, the superoxide dismutase gene takes that superoxide, and it breaks it down into hydrogen peroxide
The least common ongoing side effects were suicidal thoughts (8%), allergies (12%) and vomiting (14%)
The Lancet Diabetes & Endocrinology , 12(3), 201-213